Caris Life Sciences (CAI) Debt to Equity (2024 - 2026)

Caris Life Sciences' Debt to Equity history runs 3 years deep, the most recent figure standing at $0.64 for Q1 2026.

• In Q1 2026, Debt to Equity changed N/A year-over-year to $0.64; the TTM figure through Mar 2026 stood at $0.64 (changed N/A YoY), while the FY2025 annual figure was $0.66, up 532.23% from the prior year.
• Debt to Equity was $0.64 for Q1 2026 at Caris Life Sciences, down from $0.66 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.83 in Q2 2025 to a low of -$0.15 in Q4 2024.
• Historically, Debt to Equity has averaged $0.55 across 3 years, with a median of $0.66 in 2025.
• Biggest YoY gain for Debt to Equity was 532.23% in 2025; the steepest drop was 532.23% in 2025.
• A 3-year view of Debt to Equity shows it stood at -$0.15 in 2024, then surged by 532.23% to $0.66 in 2025, then slipped by 2.06% to $0.64 in 2026.
• The last three Debt to Equity figures came in at $0.64 (Q1 2026), $0.66 (Q4 2025), and $0.79 (Q3 2025), per Business Quant data.